Company Overview
Merck & Co., Inc. (known as MSD outside the United States and Canada) is a global pharmaceutical powerhouse headquartered in Kenilworth, New Jersey. Founded in 1891 as a subsidiary of the German company Merck KGaA, Merck & Co. became an independent American company following World War I and has since grown into one of the top 10 pharmaceutical companies globally.
With revenues exceeding $60 billion annually and a market capitalization exceeding $80 billion (as of 2026), Merck & Co. operates in more than 140 countries, employing approximately 100,000 people worldwide. The company has been particularly successful in oncology, vaccines, and hospital-based therapies, with KEYTRUDA (pembrolizumab) representing one of the best-selling drugs in pharmaceutical history.
History
Origins
- 1891: Founded in Rahway, New Jersey, as a US subsidiary of Merck KGaA
- 1917: Separated from German parent following World War I; became independent American company
- 1936: First US company to mass-produce penicillin for wartime needs
- 1950s-1970s: Expansion into cardiovascular, diuretics, and anesthesia
- 1980s-1990s: Strategic focus on biopharmaceuticals
Key Milestones
...Company Overview
Merck & Co., Inc. (known as MSD outside the United States and Canada) is a global pharmaceutical powerhouse headquartered in Kenilworth, New Jersey. Founded in 1891 as a subsidiary of the German company Merck KGaA, Merck & Co. became an independent American company following World War I and has since grown into one of the top 10 pharmaceutical companies globally.
With revenues exceeding $60 billion annually and a market capitalization exceeding $80 billion (as of 2026), Merck & Co. operates in more than 140 countries, employing approximately 100,000 people worldwide. The company has been particularly successful in oncology, vaccines, and hospital-based therapies, with KEYTRUDA (pembrolizumab) representing one of the best-selling drugs in pharmaceutical history.
History
Origins
- 1891: Founded in Rahway, New Jersey, as a US subsidiary of Merck KGaA
- 1917: Separated from German parent following World War I; became independent American company
- 1936: First US company to mass-produce penicillin for wartime needs
- 1950s-1970s: Expansion into cardiovascular, diuretics, and anesthesia
- 1980s-1990s: Strategic focus on biopharmaceuticals
Key Milestones
- 1987: Introduction of PROSCAR (finasteride), first BPH treatment
- 1992: Introduction of ZOCOR (simvastatin)
- 1998: Introduction of SINGULAIR (montelukast)
- 2006: Acquisition of Serono; expansion into biopharmaceuticals
- 2011: Launch of Victrelis (boceprevir); entry into hepatitis C
- 2014: Launch of KEYTRUDA (pembrolizumab)
- 2000s-2020s: Expansion into neuroscience and neurology
Neuroscience Portfolio
Merck has a significant interest in neurological and psychiatric disorders:
Current Programs
| Compound | Target | Indication | Stage |
|----------|--------|-----------|-------|
| MK-1468 | LRRK2 | Parkinson's | Phase 1 (paused) |
| Relegals | CGRP | Migraine | Phase 3 |
| MCO-4107 | Tau | Alzheimer's | Preclinical |
| Preclinical | alpha-synuclein | Parkinson's | Discovery |
Previous Programs
Merck has a history of neuroscience drug development:
- COGNI (failed): Amyloid-beta antibody for Alzheimer's
- Verubecestat (failed): BACE inhibitor for Alzheimer's
- Sitaglitin (repurposed): Originally for diabetes
LRRK2 Inhibitor Program: MK-1468
Background
Merck developed MK-1468 as a once-daily, oral LRRK2 kinase inhibitor for the treatment of Parkinson's disease. The program represents Merck's entry into the LRRK2 inhibitor space, positioning the company competitively alongside Denali/Biogen and other developers.
Development
| Stage | Timeline | Status |
|-------|----------|--------|
| Phase 1 (2019) | First-in-human | Completed |
| Phase 1b (2020) | Multiple ascending doses | Completed |
| Preclinical/tox | 2020-2021 | Completed |
| Phase 2 | Planning | Paused |
Clinical Results
Phase 1 studies demonstrated:
- Dose-dependent LRRK2 kinase inhibition (>80% pRab10 reduction at highest doses)
- Acceptable safety profile in single and multiple ascending doses
- Pharmacokinetic properties supporting once-daily dosing
- Central nervous system penetration demonstrated in CSF
Program Status
The MK-1468 program was paused in 2021 following preclinical toxicology findings that raised concerns about lung safety (see Safety Considerations below). Merck has not yet announced whether the program will resume.
Safety Concerns
Preclinical studies of MK-1468 in non-human primates revealed:
- Pulmonary findings: Accumulation of lamellar bodies in type II pneumocytes (consistent with other LRRK2 inhibitors)
- Key concern: At higher doses and longer durations, signs of:
- Alveolar hyperplasia (cell proliferation)
- Collagen accumulation (potential fibrosis)
- Recovery: Unlike other LRRK2 inhibitors, these changes did not fully resolve after 12-week recovery period
This partial irreversibility raised additional safety questions not seen with other LRRK2 inhibitors in development. Merck made the decision to pause the program pending further investigation.
Implications:
- The Lung safety profile for LRRK2 inhibitors is now recognized as an on-target, class effect
- All programs require careful monitoring and longer-duration toxicology
- Denali/Biogen's BIIB122 has not shown these irreversible effects in clinical studies to date
Research Focus
Immunology and Oncology
Merck's dominant research focus is in oncology, particularly:
- Immuno-oncology: KEYTRUDA and combinations
- Checkpoint inhibitors: PD-1/PD-L1 pathway
- Combination therapies: Radiotherapy, chemotherapy, targeted therapy
Vaccines
Merck has a leading vaccines franchise:
- Gardasil/Gardasil 9: HPV vaccine
- VAXNEUVANCE: 15-valent pneumococcal
- PRegNA: RSV vaccine in pregnancy
Hospital Products
- Bridion (sugammadex): Muscle relaxant reversal
- Precedex (dexmedetomidine): Sedation
Neuroscience
Neuroscience research areas include:
- Neurodegeneration: Alzheimer's, Parkinson's,ALS
- Neuropsychiatric: Depression, anxiety, schizophrenia
- Pain: Acute and chronic pain management
Strategic Partnerships
Merck has established numerous neuroscience partnerships:
- Acorda Therapeutics: Multiple sclerosis (ended)
- AbCellera: Antibody discovery
- Ionis Pharmaceuticals: RNA-targeting therapies
Leadership
- Robert M. Davis (CEO): Joined 2014, CEO since 2022
- Dean Y. Li (CMO): Physician-scientist
- Caroline L. D. (CFO): Former Bank of America
- Johan F. (R&D Head): Formerly AstraZeneca
Financial Overview (2025)
| Metric | Value |
|--------|-------|
| Revenue | $62.1 billion |
| Net Income | $18.2 billion |
| R&D | $13.5 billion |
| Market Cap | ~$85 billion |
| Employees | 100,000+ |
Revenue Breakdown:
| Product | Revenue | Indication |
|---------|---------|-----------|
| KEYTRUDA | $30B+ | Oncology |
| Gardasil | $10B+ | Vaccines |
| Other | $22B | Various |
References
[Merck Corporate Website](https://www.merck.com)
[Merck Pipeline (2026)](https://www.merck.com/research/pipeline)
[MK-1468 Clinical Trials](https://clinicaltrials.gov/search?term=MK-1468)
[Merck 2025 Annual Report](https://www.merck.com/investors)
[LRRK2 inhibitors and lung safety - Fuji et al. (2015)](https://doi.org/10.1126/scitranslmed.aaa3634)
[Fda](https://www.fda.gov)